XFOR XFOR
Company Profile ↓Company Overview
XFOR (XFOR) is a publicly traded company listed on with a market capitalization of $329.08M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $35.11M (+1273.2% YoY); net profit $-79.20M.
- Trailing 12 Months Year-on-year growth — revenue +1273.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 1,273.21% |
Stock Price Performance
| 1 Year: | +10.37% |
| 6 Months: | +1.69% |
| 3 Months: | -11.27% |
| 1 Month: | -14.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 3.50M | 0 | 0 | 0 | 3.00M | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | 0 | 563.00K | 560.00K | - | 28.81M | 1.97M | 1.76M | 2.57M | 2.71M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.72M | 326.00K | 351.00K | 364.00K | 598.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.09M | 1.65M | 1.41M | 2.20M | 2.11M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.53M | 27.88M | 28.92M | 25.90M | 22.42M |
| Operating Income | -5.83M | -5.64M | -13.06M | - | -6.11M | -6.38M | -8.54M | - | -10.44M | -13.41M | -16.98M | -10.58M | -14.66M | -16.98M | -17.94M | -19.00M | -19.12M | -21.27M | -20.57M | -20.15M | -29.30M | -25.80M | -27.21M | -37.29M | 71.10M | -34.50M | - | -9.44M | -26.23M | -27.51M | -23.70M | -20.31M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.99M | -23.12M | -27.36M | -21.52M | -17.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.20M | 2.23M | 2.26M | 2.19M | 2.13M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 316.00K | -25.70M | -29.84M | -23.93M | -20.24M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.00K | 37.00K | -30.00K | 0 | 0 |
| Net Income | -5.38M | -5.71M | -11.60M | -11.19M | -7.37M | -6.03M | -8.60M | -9.36M | -10.87M | -13.38M | -17.71M | -11.14M | -15.14M | -17.45M | -18.68M | -19.64M | -20.18M | -21.96M | -21.21M | -21.59M | -24.02M | -55.71M | -2.31M | -51.77M | 90.83M | -36.70M | - | 282.00K | -25.74M | -29.82M | -23.93M | -20.24M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.76 | -0.72 | -0.60 | -0.26 | -0.16 | -0.33 | -0.01 | -7.77 | 13.57 | -5.48 | -6.00 | 0.04 | -3.47 | -0.69 | - | -0.16 |
| R&D Expense | 4.39M | 3.91M | 10.60M | - | 4.74M | 4.75M | 6.16M | - | 5.66M | 8.85M | 8.59M | 8.91M | 9.34M | 11.38M | 12.10M | 13.19M | 13.19M | 14.11M | 13.82M | 14.11M | 22.06M | 15.60M | 19.08M | 19.85M | 20.91M | 19.17M | - | 18.51M | 18.35M | 17.34M | - | 15.45M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 3.00M | - | 0 | 0 | 2.56M | 35.11M |
| Cost of Revenue | - | - | - | - | - | - | 0 | 0 | 797.00K | 5.76M |
| Gross Profit | - | - | - | - | - | - | 0 | 0 | 1.76M | 29.36M |
| Operating Expenses | - | - | - | - | - | - | 88.08M | 107.52M | 143.16M | 116.24M |
| Operating Income | -24.35M | -22.25M | -29.09M | -51.70M | -59.87M | - | -88.08M | -107.52M | -141.40M | -86.88M |
| EBITDA | - | - | - | - | - | - | -89.33M | -94.89M | -27.58M | -69.00M |
| Interest Expense | - | - | - | - | - | - | 3.99M | 5.78M | 8.77M | 8.88M |
| Pretax Income | - | - | - | - | - | - | -93.84M | -101.09M | -37.14M | -79.16M |
| Tax Provision | - | - | - | - | - | - | 28.00K | 78.00K | 310.00K | 41.00K |
| Net Income | -22.98M | -21.99M | -33.28M | -52.81M | -62.13M | - | -93.87M | -101.17M | -37.45M | -79.20M |
| Diluted EPS | - | - | - | - | -3.09 | - | -45.60 | -17.07 | -5.70 | -1.87 |
| R&D Expense | 17.83M | 17.07M | 20.35M | 30.16M | 41.93M | 50.65M | 61.06M | 72.02M | 81.64M | 72.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 81.25M | 9.94M | 160.70M | 122.87M | - | 155.59M | 147.26M | 146.45M | 290.46M |
| Current Assets | - | - | - | - | - | - | - | 128.68M | 122.08M | 112.17M | 261.58M |
| Cash & Equivalents | - | 15.16M | 26.68M | 8.13M | 126.18M | 78.71M | - | 121.72M | 99.22M | 55.70M | 217.05M |
| Inventory | - | - | - | - | - | - | - | - | 0 | 2.82M | 4.48M |
| Receivables | - | - | - | - | - | - | - | - | 0 | 1.07M | 573.00K |
| Total Liabilities | - | - | 22.55M | 21.62M | 31.48M | 50.07M | - | 81.53M | 96.16M | 124.30M | 104.17M |
| Current Liabilities | - | - | 10.68M | 7.91M | 9.45M | 11.95M | - | 22.32M | 22.86M | 32.88M | 25.76M |
| Long Term Debt | - | - | - | 8.31M | 20.00M | 33.18M | - | 32.30M | 54.57M | 75.42M | 76.29M |
| Total Debt | - | - | - | - | - | - | - | 38.42M | 58.28M | 78.09M | 77.28M |
| Total Equity | -34.32M | -23.05M | -44.55M | -77.09M | 129.22M | 72.80M | - | 74.05M | 51.10M | 22.15M | 186.29M |
| Shares Outstanding | - | - | - | - | - | - | - | 4.06M | 5.58M | 5.70M | 90.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.64M | -21.31M | -25.42M | -48.05M | -58.82M | - | -77.10M | -96.51M | -130.90M | -85.62M |
| Investing Cash Flow | -73.00K | -378.00K | 0 | 27.23M | -1.36M | - | -103.00K | -14.88M | 66.99M | 8.15M |
| Financing Cash Flow | 18.15M | 33.42M | 6.87M | 140.66M | 12.39M | - | 117.23M | 88.52M | 20.29M | 238.63M |
| Capital Expenditure | - | - | - | - | - | - | -103.00K | -60.00K | -7.33M | -3.00M |
| Free Cash Flow | - | - | - | - | - | - | -77.20M | -96.57M | -138.23M | -88.62M |
| Net Change in Cash | - | - | - | - | - | - | 40.02M | -22.88M | -43.62M | 161.16M |
| Share Buybacks | - | - | - | 0 | 0 | 2.00M | 0 | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 68.8% | 83.6% |
| Operating Margin % | - | - | - | - | -1,995.8% | - | - | - | -5,530.0% | -247.4% |
| Net Margin % | - | - | - | - | -2,071.0% | - | - | - | -1,464.6% | -225.6% |
| ROE % | 99.7% | 49.4% | 43.2% | -40.9% | -85.3% | - | -126.8% | -198.0% | -169.1% | -42.5% |
| ROCE % | - | -31.5% | -1,427.8% | -34.2% | -54.0% | - | -66.1% | -86.4% | -124.5% | -32.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Morgan Stanley | 9.54% | 9.46M | $38.22M |
| 2 | FMR, LLC | 8.39% | 8.32M | $33.62M |
| 3 | Bain Capital Life Sciences Investors, LLC | 8.04% | 7.97M | $32.19M |
| 4 | Perceptive Advisors Llc | 8.00% | 7.93M | $32.05M |
| 5 | Saturn V Capital Management LP | 7.03% | 6.97M | $28.17M |
| 6 | Empery Asset Management, LP | 6.99% | 6.93M | $28.00M |
| 7 | Deep Track Capital, Lp | 5.93% | 5.88M | $23.75M |
| 8 | Blackrock Inc. | 5.60% | 5.55M | $22.44M |
| 9 | Vanguard Capital Management LLC | 3.75% | 3.72M | $15.01M |
| 10 | Kalehua Capital Management LLC | 3.75% | 3.72M | $15.04M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XFOR
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal…
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nas…
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the company issued inducemen…
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients wi…
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the company issued inducement aw…
XFOR — Frequently Asked Questions
What is the current share price of XFOR?
As of 2026-09-16 18:39 PDT, XFOR trades at $3.62 on NASDAQ/NYSE. Its 52-week range is $2.86 to $4.67.
What is the market capitalisation of XFOR?
XFOR has a market capitalisation of $329.08M on NASDAQ/NYSE.
What is the P/E ratio of XFOR?
XFOR trades at a trailing price-to-earnings (P/E) ratio of -1.94. Its price-to-book (P/B) ratio is 2.26.
What is the return on equity (ROE) of XFOR?
XFOR has a return on equity (ROE) of -42.51%. Its return on capital employed (ROCE) is -32.82%.
Is XFOR a good stock to buy?
This page provides a data-driven analysis of XFOR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.